Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancer

Abstract : Gastric or gastro-oesophageal junction (GEJ) adenocarcinomas present poor overall survival (OS). First-line chemotherapy regimen for patients with HER2-negative tumours is based on a doublet or triplet of fluoropyrimidine plus platinum salt ± taxane. Second-line chemotherapy (Docetaxel or Irinotecan) improves OS which nonetheless remains poor (around 5 months). The first results of immune checkpoint inhibitors (anti-PD-1) combined with chemotherapy in metastatic gastric and GEJ cancers were discordant in recent phase III trials. Data on dual-blockade (anti-PD-L1 or anti-PD-1 plus anti-CTLA-4) plus chemotherapy are lacking. DURIGAST is a randomised, multicenter, non-comparative, phase II study, evaluating safety and efficacy of FOLFIRI plus Durvalumab (anti-PD-L1) versus FOLFIRI plus Durvalumab and Tremelimumab (anti-CTLA-4) as second-line treatment of advanced gastric and GEJ adenocarcinoma. The primary objective is the rate of patients alive and without progression at 4 months. The main inclusion criteria are: patients with advanced gastric or GEJ adenocarcinoma, pre-treated with fluoropyrimidine + platinum salt ± taxane. Due to a lack of data on FOLFIRI, Durvalumab and Tremelimumab combination, a 2-step safety run-in phase has been performed before the randomised phase II. The safety run-in phase did not show any safety issue and the randomised phase II starts in September 2020.
Liste complète des métadonnées

https://hal.archives-ouvertes.fr/hal-03102304
Contributeur : Laurent Jonchère <>
Soumis le : lundi 22 février 2021 - 14:09:30
Dernière modification le : mardi 23 février 2021 - 15:44:07

Fichier

 Accès restreint
Fichier visible le : 2021-06-21

Connectez-vous pour demander l'accès au fichier

Identifiants

Citation

Camille Evrard, Christophe Louvet, Farid El Hajbi, Frédéric Di Fiore, Karine Le Malicot, et al.. PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancer. Digestive and Liver Disease, WB Saunders, 2021, ⟨10.1016/j.dld.2020.11.036⟩. ⟨hal-03102304⟩

Partager

Métriques

Consultations de la notice

90